Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases

被引:1
作者
Mendiola, Christina [1 ]
Ortega, Veronica [1 ]
Tonk, Vijay S. [2 ]
Coviello, Jean M. [3 ]
Velagaleti, Gopalrao [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA
[2] Texas Tech Univ, Dept Pediat, Lubbock, TX 79409 USA
[3] San Antonio Mil Med Ctr, Dept Pathol, San Antonio, TX USA
关键词
BCR/ABL; Variant translocation; CML; D-FISH; Complex rearrangement; CHRONIC MYELOID-LEUKEMIA; VARIANT TRANSLOCATIONS; CHROMOSOMES; EVOLUTION; PH1;
D O I
10.1016/j.yexmp.2014.06.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In 5-10% of cases with CML, variant or complex translocations (CT) are seen that may result in atypical fluorescence in situ hybridization signal patterns. Dual color, dual fusion fluorescence in situ hybridization (D-FISH) patterns are instrumental in identifying the genesis of these CT, but their prognostic implications remain controversial. The most common mechanism is a two-step process in which a standard two-way translocation (9;22) is followed by subsequent rearrangements involving other chromosomes. The second common mechanism is the one-step process wherein breakage occurs simultaneously on different chromosomes leading to CT. The typical D-FISH pattern seen with the one-step mechanism is 1F2G2R, while the pattern for the two-step mechanism can be variable (2F1G1R, 1F1G1R, 1F1G2R, 1F2G1R, etc.). We have studied 4 cases of CT using metaphase FISH with triple color, dual fusion ASS1, ABL1 and BCR probes to understand the genesis of these CT. All the patients were treated with imatinib, but only patients 3 and 4 showed remission. Our results indicate that the CT in cases 1,3 and 4 arose from a one-step mechanism and case 2 from a multi-step mechanism. Response to imatinib varied from full remission to no response. Long term follow-up is necessary to evaluate the prognostic implications of these CT. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 50 条
  • [31] HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML)
    Posthuma, EFM
    Falkenburg, JHF
    Apperley, JF
    Gratwohl, A
    Hertenstein, B
    Schipper, RF
    Oudshoorn, M
    von Biezen, JH
    Hermans, J
    Willemze, R
    Roosnek, E
    Niederwieser, D
    LEUKEMIA, 2000, 14 (05) : 859 - 862
  • [32] Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML)
    Klyuchnikov, Evgeny
    Kroeger, Nicolaus
    Brummendorf, Tim H.
    Wiedemann, Bettina
    Zander, Axel Rolf
    Bacher, Ulrike
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) : 301 - 310
  • [33] ALL- and CML-type BCR ABL mRNA transcripts in chronic myelogenous leukemia and related disorders
    Yokohama, A
    Karasawa, M
    Okamoto, K
    Sakai, H
    Naruse, T
    LEUKEMIA RESEARCH, 1999, 23 (05) : 477 - 481
  • [34] Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia
    Jarkowski, Anthony, III
    Sweeney, Richard P.
    PHARMACOTHERAPY, 2008, 28 (11): : 1374 - 1382
  • [35] Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches
    Asnafi, Ali Amin
    Zayeri, Zeinab Deris
    Shahrabi, Saeid
    Zibara, Kazem
    Vosughi, Tina
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5798 - 5806
  • [36] Guidelines for the management of nilotinib (Tasigna®)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)
    Etienne, G.
    Milpied, B.
    Rea, D.
    Rigal-Huguet, F.
    Tulliez, M.
    Nicolini, F. -E.
    BULLETIN DU CANCER, 2010, 97 (08) : 997 - 1009
  • [37] Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
    Robert, Guillaume
    Ben Sahra, Issam
    Puissant, Alexandre
    Colosetti, Pascal
    Belhacene, Nathalie
    Gounon, Pierre
    Hofman, Paul
    Bost, Frederic
    Cassuto, Jill-Patrice
    Auberger, Patrick
    PLOS ONE, 2009, 4 (11):
  • [38] Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission:: CML or sensitivity of detection?
    Anguita, E
    Villegas, A
    Díaz-Mediavilla, J
    González, FA
    Del Potro, E
    Espinós, D
    HAEMATOLOGICA, 1998, 83 (08) : 744 - 747
  • [39] Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis
    Nakamura, Yukitsugu
    Tokita, Katsuya
    Nagasawa, Fusako
    Takahashi, Wataru
    Nakamura, Yuko
    Sasaki, Ko
    Ichikawa, Motoshi
    Mitani, Kinuko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 348 - 353
  • [40] Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome
    Dayane B. Koshiyama
    Marcelo E. Z. Capra
    Giorgio A. Paskulin
    Rafael F. M. Rosa
    Ceres A. V. Oliveira
    Tito Vanelli
    Laura M. Fogliatto
    Paulo R. G. Zen
    Annals of Hematology, 2013, 92 : 185 - 189